Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination, Immunity and Aging Research
NL-OMON23996Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Sep 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine and influenza vaccine in pneumococcal disease and influenza, sponsored by National Institute for Public Health and the Environment. Primary endpoint: Antibody response to pneumococcal and influenza vaccination in relation to frailty. Started Sep 2020; status: active, not recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccineinfluenza vaccine
03
Conditions
pneumococcal diseaseinfluenza
Beyond the preview
Go deeper on NL-OMON23996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23996.